8-K: PowerUp Acquisition Corp. Agrees to $1 Million Fee for Sponsor After Terminated Visiox Deal

PowerUp Acquisition Corp. will pay its sponsor a $1 million fee upon the successful closing of a business combination with Aspire Biopharma, after a previous deal with Visiox Pharmaceuticals was terminated.

Summary

• PowerUp Acquisition Corp. (SPAC) had a previous agreement with Visiox Pharmaceuticals that included a $2 million fee for the sponsor, SRIRAMA Associates, LLC, upon successful closing of the deal.
• This deal was terminated, and the sponsor's right to the $2 million fee was also terminated.
• PowerUp has now agreed to pay the sponsor a modified fee of $1 million upon the successful closing of a new business combination with Aspire Biopharma.
• This modified fee is in recognition of the risk the sponsor took by providing a $2 million bridge loan to Visiox.
• The agreement was formalized on October 2, 2024, and is contingent on the successful closing of the Aspire Biopharma deal.

Sentiment

Score: 6

Explanation: The document reflects a neutral to slightly positive sentiment. While a previous deal failed, the company has secured a new target and is compensating the sponsor for their risk. The modified fee is lower than the original, which is a positive for the company.

Positives

• The sponsor is being compensated for the risk taken in providing a bridge loan, despite the initial deal falling through.
• The agreement provides clarity on the payment terms for the sponsor in the new business combination with Aspire Biopharma.

Negatives

• The company had to pay a fee to the sponsor even though the initial business combination did not occur.
• The company is paying a fee of $1 million, which is a reduction from the original $2 million, but still a significant expense.

Risks

• The $1 million fee is contingent on the successful closing of the business combination with Aspire Biopharma, which is not guaranteed.
• The company has already had one business combination agreement terminated, which could indicate potential challenges in completing future deals.

Future Outlook

The payment of the $1 million fee is contingent on the successful closing of the business combination with Aspire Biopharma.

Management Comments

• The company acknowledged that the sponsor took significant risk by entering into the Visiox Promissory Note.
• The company agreed that the sponsor should be compensated for that risk despite the termination of the Visiox deal.

Industry Context

This announcement is typical of SPAC transactions, where sponsors often receive fees for their efforts in identifying and securing a target company. The renegotiation of fees after a deal termination is also not uncommon.

Comparison to Industry Standards

• SPAC sponsor fees typically range from 2% to 5% of the gross proceeds raised in the IPO, but this fee is a modified fee due to a failed merger.
• Bridge loans are common in SPAC transactions to provide working capital to target companies, and sponsors are often compensated for the risk of providing these loans.
• The $1 million fee is a reduction from the original $2 million, which is a common outcome when a deal is terminated and renegotiated.

Related Party Transactions

• The agreement is between PowerUp Acquisition Corp. and its sponsor, SRIRAMA Associates, LLC, which is a related party transaction.

Stakeholder Impact

• Shareholders will be impacted by the $1 million fee, which will be an expense for the company.
• The sponsor will benefit from the $1 million fee upon successful closing of the Aspire Biopharma deal.

Next Steps

• The company needs to successfully close the business combination with Aspire Biopharma to trigger the payment of the $1 million fee.
• The company will need to continue to work towards completing the business combination with Aspire Biopharma.

Key Dates

Keywords

business combination, SPAC, promissory note, sponsor fee, acquisition, SRIRAMA Associates, PowerUp Acquisition Corp, Aspire Biopharma, Visiox Pharmaceuticals